Ingersoll Rand (IR) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus is a manageable bar with organic revenue expected flattish-to-slightly-up and EPS of ~$0.82–$0.83, but the real swing factor is whether ITS margin trajectory shows the sequential improvement management guided (50–100 bps below prior year), as any further compression would reignite concerns about the 2027 margin target.

Heading into Q2 2026, the bar for Ingersoll Rand is achievable but not low. Consensus sits at $0.82–$0.83 in adjusted EPS and ~$1.96B in revenue, consistent with management's own Q2 guidance of organic revenue "flattish to slightly up" and EBITDA delivery in the 45.5%–46% first-half range of the full-year total. Management's posture on the Q1 call was measured confidence — full-year guidance was reaffirmed despite Middle East order delays (~$40M, ~1/3 already recovered in April) and ongoing tariff headwinds, with the tone shifting toward execution mode as all tariff-related pricing actions were largely implemented through 2025. Estimate revisions since the Q1 print have been essentially flat, with the 2Q 2026 EPS consensus barely moving from $0.82 at the post-Q1 baseline to $0.82 currently, suggesting the street is largely in line with guidance rather than pricing in upside. The stock has recovered ~4% since the Q1 earnings-day selloff (which was a ~5% decline despite a beat), trading back near $84–$86, implying the market has partially re-rated the story but has not yet priced in a meaningful beat. The key wildcard is the pace of

short-cycle industrial recovery — U.S. ISM turned positive for the first time in many months, and peers including Parker Hannifin (PH), Dover (DOV), and Rockwell (ROK) have all reported improving broad-based industrial demand in Q2 2026, which could provide a positive read-through for ITS organic orders and revenue conversion. If ITS margins show the guided sequential improvement and PST continues its double-digit life sciences order momentum, IR has a credible path to a modest beat; if ITS margins disappoint again, the stock will likely re-test its post-Q1 lows.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar — organic revenue "flattish to slightly up" is already baked in, and the $0.82–$0.83 EPS estimate is consistent with management's H1 EBITDA phasing guide. ITS segment margin is the bigger swing factor: a fifth consecutive quarter of year-over-year compression is expected (50–100 bps), but any further deterioration beyond that range would be a negative surprise.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data (Net revenues, EBITDA - Operating, EBITDA margin - operating(%), EPS - Diluted - Operating($), Revenue - Industrial technology, Revenue - Precision and Science Technologies, EBITDA margin - Industrial technology - operating(%), EBITDA margin - Precision and Science Technologies - operating(%), Organic impact(%)); Q1 2026 Earnings Call Transcript (April 29, 2026).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Adj. EPS & Total Revenue)

Pattern: IR has beaten EPS consensus in 5 of the last 8 quarters, with beats concentrated in Q2 2024, Q4 2025, and Q1 2026; revenue beats have been more consistent but modest in magnitude. The one EPS miss (Q1 2025) coincided with the onset of tariff headwinds. The pattern suggests management guides conservatively on EPS, creating a modest but reliable beat cadence when execution is clean.

Source: Visible Alpha Consensus and Actuals Data (EPS - Diluted - Operating($), Net revenues).

3. Guidance & Commentary Evolution

Key Takeaway: Full-year 2026 guidance was reaffirmed in full on the Q1 call with no changes — no post-earnings revisions have been issued. Management tone has shifted from cautious to measured confidence, with tariff pricing actions fully implemented and the price-cost dynamic expected to turn more positive in H2.

Source: Q1 2026 Earnings Call Transcript (April 29, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 2026 EPS consensus has barely moved ($0.82 vs. $0.82 at baseline) and FY 2026 EPS is essentially flat ($3.50 vs. $3.51 at baseline). This tells us the street is tracking guidance closely with no incremental optimism or pessimism baked in, leaving the setup balanced rather than stretched.

Estimates have been essentially anchored to guidance since the Q1 print, with virtually zero revision in either direction across all key KPIs. This is consistent with management's reaffirmation of full-year guidance and the street's view that the Q2 setup is well-telegraphed. The lack of upward revision despite improving peer data points (ROK, DOV, PH all beat in Q2) suggests there may be modest upside optionality if ITS short-cycle demand has continued to improve through June.

Source: Visible Alpha Consensus and Actuals Data (as of May 5, 2026 baseline and current); Q1 2026 Earnings Call Transcript.

5. Stock Performance

Key Takeaway: IR has recovered ~+4.2% since the Q1 earnings-day selloff, modestly outperforming XLI (+3.3%), but the stock remains well below its 52-week highs. The recovery has been driven by improving industrial sentiment and peer read-throughs rather than estimate revisions, which have been flat — suggesting the re-rating is sentiment/multiple-driven and could be fragile if Q2 margins disappoint.

IR vs. XLI (Industrials Select Sector SPDR ETF) — Indexed to 100 at Q1 2026 Earnings Date (April 28, 2026). IR: +4.2%; XLI: +3.3% through July 30, 2026. Material events marked: Fox S.r.l. close (May 4), Incentive Plan Approval (June 16), Q2 Earnings Scheduled announcement (July 1).

IR declined ~5% on the Q1 earnings day (April 28–29) despite beating EPS by $0.03 and revenue by ~$16M, as the market focused on the fifth consecutive quarter of ITS margin compression and the Middle East order delay. The stock bottomed near $68–$70 in mid-May before recovering through June and July as industrial peers reported improving demand trends. The July 16 session saw a notable single-day spike to $84.78, likely driven by positive peer read-throughs from ITW (Q2 2026 beat, July 28) and broader industrial sector re-rating. IR has modestly outperformed XLI since the Q1 print (+4.2% vs. +3.3%), suggesting the stock has partially re-rated on improving sentiment but has not yet priced in a meaningful Q2 beat. The sector ETF (XLI) is used as the benchmark given IR's classification in the Industrials sector.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the continued M&A execution (Fox S.r.l. closed May 4, three additional bolt-ons in life sciences) and the improving industrial demand backdrop from peers — both are incrementally positive for the Q2 print and the H2 recovery thesis.

• May 4, 2026 — Fox S.r.l. Acquisition Closed: Fox S.r.l. (hydropneumatic accumulators and pulsation dampeners, Italy) officially joined the PST segment. This was the first deal to close post-Q1 and contributes to the ~2% M&A revenue growth embedded in FY 2026 guidance. Implication: Incremental PST revenue in Q2 2026; consistent with 400–500 bps annualized inorganic revenue target.
• Q2 2026 YTD — Three Additional Life Sciences Bolt-Ons: Lead Fluid (pump technology), Senomyx (lab automation), and Dave Berry Plastics (biopharma-complementary) were closed in 2026 per the Q1 call. Implication: Accelerates PST life sciences platform buildout; biopharma reshoring tailwind continues to support demand.
• June 16, 2026 — Shareholders Approve New Omnibus Incentive Plan (8-K): Routine governance action; no financial impact. Implication: No material read-through for Q2 results.
• July 1, 2026 — Q2 2026 Earnings Release Scheduled: IR formally announced Q2 2026 results for July 30, 2026 after market close, with conference call July 31 at 8:00 AM ET. Implication: No pre-announcement or guidance revision issued alongside the scheduling — consistent with guidance being on track.
• April 2026 — Middle East Order Recovery: Management confirmed on the Q1 call that approximately one-third of the ~$40M in delayed Middle East long-cycle orders had already been recovered in April. Implication: Reduces the risk of a Q2 revenue miss from this item; remaining ~$27M expected to recover through H2 2026.
• Ongoing — U.S. ISM Turned Positive: The U.S. ISM Manufacturing PMI moved above 50 for the first time in many months, consistent with management's commentary on short-cycle stabilization. Implication: Positive read-through for ITS compressor and tool demand in Q2; supports the low single-digit organic growth guide for Q2–Q4.
• Ongoing — Biopharma Reshoring Tailwind: Multiple peers (ROK, DOV, AME) cited continued strength in life sciences and biopharma demand, particularly around API production and GLP-1 manufacturing in the U.S. Implication: Positive read-through for IR's PST life sciences business (~$600–$700M total, with ILC Dover biopharma ~$200M growing double digits).
• Ongoing — Rising European Energy Prices: Gas prices in Europe have spiked (though not to 2022 levels), which management cited as a potential longer-term tailwind for IR's energy-efficient compressor and blower products. Implication: Supports ITS demand in EMEA; not yet a near-term revenue driver but positive for the order funnel.
• No Analyst Rating Changes Found: No upgrade or downgrade data was identified for IR in the post-Q1 window (April 28 – July 29, 2026).

7. Peer Commentaries — Read-Through (Last 60 Days, Q2 2026 Relevant)

Key Takeaway: Peer commentary from Q2 2026 earnings and recent conferences is broadly constructive for IR — industrial demand is broadening, short-cycle activity is improving, life sciences/biopharma remains strong, and tariff headwinds are being managed through pricing. The most relevant read-throughs are from Dover (DOV), Rockwell (ROK), and Parker Hannifin (PH) — all of which reported improving industrial demand, positive book-to-bill, and tariff neutrality in Q2 2026.

Note: Only peer commentary from Q2 2026 earnings calls and post-Q1 conferences (i.e., commentary about current-quarter or forward conditions) is included below. Q1 2026 results commentary from peers is excluded unless it contains explicit Q2 2026 or full-year forward guidance.

Dover Corporation (DOV) — Q2 2026 Earnings Call (July 23, 2026)

Relevance to IR: DOV's Pumps & Process Solutions segment (single-use biopharma, industrial pumps, precision components) and Clean Energy & Fueling segment (cryogenic components, LNG) are direct read-throughs for IR's PST and ITS segments respectively. DOV also competes in similar industrial end markets.

• Broad-based industrial demand with positive book-to-bill across all five segments: DOV reported Q2 2026 revenue up 7% (5% organic), with orders up 16% YoY and book-to-bill of 1.06 — the first time all five segments were above 1x simultaneously. "Our book-to-bill is solid. And because we touch so many different end markets, it's rare that we see it above one across the portfolio. So it is by definition broad based." → Positive read-through for IR's ITS book-to-bill and order momentum in Q2.
• Single-use biopharma and industrial pumps remain strong: DOV's Pumps & Process Solutions segment cited "strength in AI and energy infrastructure components, single-use biopharma, and industrial pumps." Biopharma consumables revenue is described as highly recurring. → Positive read-through for IR PST life sciences (ILC Dover biopharma ~$200M, growing double digits).
• Secular growth markets (data centers, LNG, biopharma, aerospace) driving outsized order momentum: DOV's secular growth portfolio (now ~25% of revenue) is seeing demand outpace supply in heat exchangers and CO2 refrigeration. "The cycles that we're participating in clearly have visibility into 2027." → Supports IR's thesis that long-cycle funnel remains healthy even as conversion timing is elongated.
• Tariff headwinds managed through pricing; EBITDA margin expanded 80 bps to 25.9%: DOV noted "operational execution on incremental volume more than offset input cost inflation and facility consolidation costs." Incremental margins improved to 38% in Q2 from 25% in Q1. → Positive read-through for IR's price-cost dynamic turning more positive in H2 2026.
• M&A pipeline improving: "Industrial M&A markets have improved this year, and our acquisition pipeline has a number of interesting opportunities in attractive end markets." → Consistent with IR's active M&A posture (10 LOIs, potential $1B+ deal in funnel).

Rockwell Automation (ROK) — Q2 FY2026 Earnings Call (May 5, 2026)

Relevance to IR: ROK's commentary on industrial automation demand, life sciences, and short-cycle activity is a read-through for IR's ITS and PST segments. ROK's Q2 FY2026 corresponds to the calendar quarter ending March 2026, so this is commentary about conditions in early 2026 that are relevant to IR's Q2 2026 setup.

• Industrial demand broadening across more end markets: ROK reported Q2 organic sales up 9% YoY, with "an improvement in customer demand across a broader range of industries in Q2, such as e-commerce, warehouse automation, data center, semiconductor and energy." Book-to-bill slightly above historical average. → Positive read-through for IR ITS short-cycle demand recovery.
• Life sciences grew low single digits YoY and double digits sequentially: "Our life sciences business grew low single digits versus prior year and double digits sequentially with new capacity projects in North America and Asia Pacific." Strategic win with Butantan Institute (biopharma/vaccine producer in Brazil). → Positive read-through for IR PST life sciences order momentum.
• Tariff pricing fully offsetting costs; earnings neutrality maintained: "We continue to expect pricing actions to fully recover tariff costs this year." Price contributed 3 points to organic growth in Q2, split evenly between underlying price and tariff-based pricing. → Consistent with IR's dollar-neutral tariff pricing posture.
• Full-year guidance raised significantly: ROK raised FY2026 organic sales guidance to 5%–9% (from ~4%) and EPS midpoint to $12.80 (from $11.80). "The increase is driven by volume and very strong conversion, even as CapEx spending in some verticals remain subdued." → Positive macro signal for industrial demand; supports IR's H2 organic growth recovery thesis.

Parker Hannifin (PH) — Q3 FY2026 Earnings Call (April 30, 2026)

Relevance to IR: PH's fiscal Q3 2026 (ended March 2026) is the most recent quarter before IR's Q2 2026. PH's commentary on industrial demand, short-cycle recovery, and pricing is a direct read-through for IR's ITS segment. PH's Q4 FY2026 guidance (April–June 2026) is the most relevant forward-looking data point.

• Industrial recovery broadening on both short and long cycle: PH reported Q3 FY2026 organic growth of 6.5% with orders at +9% and record backlog of $12.5B. "We saw more broad-based positivity on both short and long cycle than we did earlier this year." North America orders +7% for two consecutive quarters. → Strong positive read-through for IR ITS short-cycle demand in Q2 2026.
• Q4 FY2026 guidance (April–June 2026) implies continued momentum: PH guided Q4 FY2026 organic growth of ~4% with adjusted segment margins of 27.4%. "Industrial organic growth for both North America and International is now expected to be 2.5% for the full year." → Directly relevant to IR's Q2 2026 (same calendar quarter); supports flattish-to-slightly-up organic revenue guidance.
• Asia Pacific strongest region, up +10% organic in Q3: PH cited "continued strength in electronics and semiconductor demand" driving Asia Pacific to positive high single-digit full-year organic growth. → Positive read-through for IR's Asia ex-China growth strategy and blower/vacuum demand.
• Tariff management: no impact to earnings: "Our teams are doing a great job managing them to make sure that there's no impact to earnings." Price-cost management described as a "strong muscle for over 25 years." → Consistent with IR's tariff neutrality posture for FY 2026.
• HVAC and refrigeration up mid-single digits; energy up low single digits: Strength in commercial HVAC, refrigeration, and power generation. → Positive read-through for IR ITS compressor demand in energy and industrial end markets.

Illinois Tool Works (ITW) — Q2 2026 Earnings Call (July 28, 2026)

Relevance to IR: ITW's Q2 2026 (most recent, reported July 28) is the closest peer print to IR's Q2 2026 report. ITW's commentary on industrial demand, pricing, and margins is a direct same-quarter read-through.

• CapEx-related and industrial demand remains strong: ITW reported Q1 2026 revenue up 5% with operating margin expansion of 60 bps to 25.4%. "Industrial markets, CapEx markets, very strong, great order activity." Welding (6% organic) and Test & Measurement (5% organic, highest in 3 years) led. → Positive read-through for IR ITS industrial demand in Q2 2026.
• Price-cost modestly accretive; more pricing coming in Q2–Q4: "We continue to expect that price/cost will be modestly accretive to margins after factoring in recent tariff changes and all known material cost increases." Additional pricing actions starting in Q2. → Consistent with IR's expectation that price-cost turns more positive in H2 2026.
• Sequential margin improvement of >100 bps from Q1 to Q2 guided: "We would expect more than 100 basis points of improvement sequentially from Q1 to Q2." Full-year EPS guidance raised by $0.10. → Positive read-through for IR's guided sequential margin improvement in Q2 2026.
• Medical business "growing leaps and bounds": ITW's Specialty Products segment cited the medical business as a standout performer. → Positive read-through for IR PST life sciences and medical device sub-businesses.

Dover Corporation (DOV) / Graco (GGG) — Q2 2026 Earnings (July 23, 2026)

Relevance to IR: Graco's Q2 2026 commentary on industrial demand, short-cycle activity, and semiconductor is a read-through for IR's ITS and PST precision technology businesses.

• Industrial demand broad-based with PMI turning positive: GGG reported Q2 2026 organic orders up 5%, with the most recent 6-week booking average up 14% YoY. "The PMI start to turn positive. So we're seeing investments being made in machinery manufacturing, general industrial applications, pretty healthy MRO channels." → Positive read-through for IR ITS short-cycle compressor and tool demand.
• Semiconductor bookings up 58% in Q2; multi-year favorable trend: GGG's semiconductor business (White Knight) saw bookings up 58% in Q2, with YTD bookings growth of 33%. "All signs at this point are this is pretty sustainable. It's going to run for a while." → Positive read-through for IR PST precision technology semiconductor exposure.
• Backlog building; stronger H2 expected: GGG built backlog in both Q1 and Q2, with year-to-date backlog up $57M (+28%) from year-start. "These positive trends give us confidence in a stronger second half." → Consistent with IR's H2-weighted organic growth and margin recovery thesis.

Trane Technologies (TT) — Q1 2026 Earnings Call (April 30, 2026) + Conferences (May 2026)

Relevance to IR: TT's commentary on HVAC demand, data center cooling, and tariff management is a partial read-through for IR's ITS compressor and blower/vacuum businesses (energy efficiency, industrial HVAC applications).

• Exceptional bookings with record backlog; Q2 2026 guided +10% revenue growth: TT reported Q1 2026 organic bookings up 24% with record backlog of $10.7B (+30% vs. year-end 2025). Q2 2026 guided for ~5% organic revenue growth and EPS of $4.20–$4.25. → Positive macro signal for industrial/HVAC demand in Q2 2026.
• Tariff inflation higher than 90 days ago but manageable: "We are expecting more inflation, including from raw materials and tariffs in the year than was estimated, say, 90 days ago." Pricing guidance raised from ~1.5% to ~2% at enterprise level. → Consistent with IR's tariff pricing posture; suggests pricing environment remains supportive.
• China remains challenging; rest of Asia stronger: "China remains challenging with dynamic macro conditions." Asia Pacific bookings up high 20s, led by rest of Asia (+50%). → Consistent with IR's China self-help narrative (taking share despite weak market) and Asia ex-China growth acceleration.

AMETEK (AME) — Q1 2026 Earnings Call (April 30, 2026)

Relevance to IR: AME's Q1 2026 commentary on life sciences, defense, and industrial demand is a read-through for IR's PST segment. AME's fiscal Q1 2026 (ended March 2026) provides forward-looking color on Q2 2026 conditions.

• Record orders of $2.2B, up 23% organically; record backlog of $3.87B: AME cited broad-based strength across defense, semiconductor, power, and automation. "Every subsegment saw double-digit organic orders growth, and every division was up at least 5%." Q2 2026 guided for high single-digit sales growth and EPS of $1.96–$2.00. → Positive macro signal for industrial demand heading into Q2 2026.
• Medical end market up low double digits in Q1; mid-single digits expected for full year: AME's medical business (>20% of exposure) was "up low double digits" in Q1, led by Paragon and Record businesses. Full-year expected at mid-single digits due to tougher comps. → Positive read-through for IR PST medical device sub-business (~$100M).
• Tariff offset through pricing; core margins up 160 bps: "We believe we're going to be able to offset any inflationary costs with pricing." Core operating margins expanded 160 bps to 27.9% in Q1. Full-year guide for 35% incrementals and core margins up ~50 bps. → Positive read-through for IR's margin recovery trajectory in H2 2026.
• China up high teens in Q1, driven by process and power markets: AME's China business was "up high teens" in Q1, driven by process and power markets. → Positive read-through for IR's China self-help narrative (positive organic order growth for four consecutive quarters).

Sources: Dover Corporation Q2 2026 Earnings Call Transcript (July 23, 2026); Rockwell Automation Q2 FY2026 Earnings Call Transcript (May 5, 2026); Parker Hannifin Q3 FY2026 Earnings Call Transcript (April 30, 2026); Illinois Tool Works Q1 2026 Earnings Call Transcript (April 30, 2026); Graco Q2 2026 Earnings Call Transcript (July 23, 2026); Trane Technologies Q1 2026 Earnings Call Transcript (April 30, 2026); AMETEK Q1 2026 Earnings Call Transcript (April 30, 2026).

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells were identified in the post-Q1 window. The only Form 4 activity was a routine RSU vesting and conversion for a director — no signal value.

The only Form 4 activity identified in the April 28 – July 29, 2026 window was a routine RSU vesting for Director Michelle Swanenburg (1,876 shares, May 5, 2026). This is an obligation-driven conversion of restricted stock units to common stock — not a discretionary open-market purchase or sale. No open-market buys or sells by executives or directors were identified. The absence of insider selling ahead of the Q2 print is a mild positive signal, though the sample size is too small to draw strong conclusions.

Source: Insider Transaction Data (SEC Form 4 filings, April 28 – July 29, 2026).